|
1
|
Hsu EC, Wu KL, Tsai YM, Lee MH, Tsai MJ,
Kuo CY, Liu YC, Liang FW, Yang CJ and Hung JY: Real-world treatment
pattern and prognostic factors of stage IV lung squamous cell
carcinoma patients. Kaohsiung J Med Sci. 38:1001–1011.
2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ganti AK, Klein AB, Cotarla I, Seal B and
Chou E: Update of incidence, prevalence, survival, and initial
treatment in patients with non-small cell lung cancer in the US.
JAMA Oncol. 7:1824–1832. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Santos ES and Rodriguez E: Treatment
considerations for patients with advanced squamous cell carcinoma
of the lung. Clin Lung Cancer. 23:457–466. 2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Basnet A, Alahmadi A and Gajra A: Older
patients with lung cancer: A summary of seminal contributions to
optimal patient care. Curr Oncol Rep. 24:1607–1618. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Novello S, Kowalski DM, Luft A, Gümüş M,
Vicente D, Mazières J, Rodríguez-Cid J, Tafreshi A, Cheng Y, Lee
KH, et al: Pembrolizumab plus chemotherapy in squamous
non-small-cell lung cancer: 5-year update of the phase III
KEYNOTE-407 Study. J Clin Oncol. 41:1999–2006. 2023.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Uprety D, Remon J and Peters S: First-line
dual immunotherapy, a treatment option in first-line metastatic
non-small-cell lung cancer: Are we ready to use it? J Clin Oncol.
42:378–382. 2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lau SCM, Pan Y, Velcheti V and Wong KK:
Squamous cell lung cancer: Current landscape and future therapeutic
options. Cancer Cell. 40:1279–1293. 2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Filipits M: New developments in the
treatment of squamous cell lung cancer. Curr Opin Oncol.
26:152–158. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Han B, Li K, Wang Q, Zhang L, Shi J, Wang
Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a
third-line or further treatment on overall survival of patients
with advanced non-small cell lung cancer: The ALTER 0303 phase 3
randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhang C, Kong FW, Wu WB, Zhang M, Yu GM,
Wang X and Liu YY: First-line pemetrexed and carboplatin plus
anlotinib for epidermal growth factor receptor wild-type and
anaplastic lymphoma kinase-negative lung adenocarcinoma with brain
metastasis: A case report and review of the literature. Medicine
(Baltimore). 99(e22128)2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Jiang S, Liang H, Liu Z, Zhao S, Liu J,
Xie Z, Wang W, Zhang Y, Han B, He J and Liang W: The impact of
anlotinib on brain metastases of non-small cell lung cancer: Post
Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
Oncologist. 25:e870–e874. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Capasso A: Vinorelbine in cancer therapy.
Curr Drug Targets. 13:1065–1071. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bilir C, Durak S, Kızılkaya B,
Hacıbekiroglu I, Nayır E and Engin H: Efficacy of metronomic
vinorelbine in elderly patients with advanced non-small-cell lung
cancer and poor performance status. Curr Oncol. 24:e199–e204.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Platania M, Pasini F, Porcu L, Boeri M,
Verderame F, Modena Y, Del Conte A, Nichetti F, Garassino MC,
Martinetti A, et al: Oral maintenance metronomic vinorelbine versus
best supportive care in advanced non-small-cell lung cancer after
platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized,
controlled, phase II trial. Lung Cancer. 132:17–23. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Grossi F, Jaśkiewicz P, Ferreira M,
Czyżewicz G, Kowalski D, Ciuffreda L, Garcia-Gomez R, Caruso S,
Bosch-Barrera J, Gautier S, et al: Oral vinorelbine and cisplatin
as first-line therapy for advanced squamous NSCLC patients: A
prospective randomized international phase II study (NAVoTrial 03).
Ther Adv Med Oncol. 13(17588359211022905)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rossi D, Lippe P, Rocchi MBL, Sarti D,
Catalano V, Graziano F, Giordani P, Baldelli A, Fedeli SL,
Imperatori L, et al: Metronomic oral vinorelbine: an alternative
schedule in elderly and patients PS2 with local/advanced and
metastatic NSCLC Not Oncogene-addicted. In Vivo. 34:2687–2691.
2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
D'Ascanio M, Pezzuto A, Fiorentino C,
Sposato B, Bruno P, Grieco A, Mancini R and Ricci A: Metronomic
chemotherapy with vinorelbine produces clinical benefit and low
toxicity in frail elderly patients affected by advanced non-small
cell lung cancer. Biomed Res Int. 2018(6278403)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xiang M, Yang X, Ren S, Du H, Geng L, Yuan
L, Wen Y, Lin B, Li J, Zhang Y, et al: Anlotinib combined with S-1
in third- or later-line stage IV non-small cell lung cancer
treatment: A phase II clinical trial. Oncologist. 26:e2130–e2135.
2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Li DD, Tao ZH, Wang BY, Wang LP, Cao J, Hu
XC and Zhang J: Apatinib plus vinorelbine versus vinorelbine for
metastatic triple-negative breast cancer who failed
first/second-line treatment: the NAN trial. NPJ Breast Cancer.
8(110)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Huang JY, Chen XL, Xie XF, Song L, Chen
LP, Lan XF, Bai X, Chen X and Du CW: The efficiency and safety of
low-dose apatinib combined with oral vinorelbine in pretreated
HER2-negative metastatic breast cancer. Cancer Med.
13(e7181)2024.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Xu H, Lv D, Meng Y, Wang M, Wang W, Zhou
C, Zhou S, Chen X and Yang H: Endostar improved efficacy of
concurrent chemoradiotherapy with vinorelbine plus carboplatin in
locally advanced lung squamous cell carcinoma patients with high
serum Lp(a) concentration. Ann Palliat Med. 9:298–307.
2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ito K, Hamamichi S, Abe T, Akagi T,
Shirota H, Kawano S, Asano M, Asano O, Yokoi A, Matsui J, et al:
Antitumor effects of eribulin depend on modulation of the tumor
microenvironment by vascular remodeling in mouse models. Cancer
Sci. 108:2273–2280. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Liao BC, Shao YY, Chen HM, Shau WY, Lin
ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang JC and Lai MS:
Comparative effectiveness of first-line platinum-based chemotherapy
regimens for advanced lung squamous cell carcinoma. Clin Lung
Cancer. 16:137–143. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li X, Wu D, Tang J and Wu Y: The
efficiency and safety of triple-drug combination of albumin-bound
paclitaxel, anlotinib and PD-1/L1 Inhibitors in the 2(nd) or above
line of advanced NSCLC: A retrospective cohort study. Cancer Manag
Res. 16:1003–1012. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tang J, Jiang H, Xiang Z, Zhu X, Xie R, Wu
D, Peng L and Li X: Apatinib plus docetaxel or pemetrexed shows
promising activities against non-small cell lung cancer with brain
metastasis: A retrospective analysis. J Thorac Dis. 16:615–622.
2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yin C, Zou GR, He Y, Li J, Yan HW, Su Z,
Cao XL and Li XB: Efficiency and toxicity of nab-paclitaxel and
camrelizumab in the second or above line treatment of advanced
non-small cell lung cancer: A retrospective cohort study. J Thorac
Dis. 15:1838–1847. 2023.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang L, He Z, Yang S, Tang H, Wu Y, Li S,
Han B, Li K, Zhang L, Shi J, et al: The impact of previous therapy
strategy on the efficiency of anlotinib hydrochloride as a
third-line treatment on patients with advanced non-small cell lung
cancer (NSCLC): A subgroup analysis of ALTER0303 trial. Transl Lung
Cancer Res. 8:575–583. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhang X, Xiong Y, Xia Q, Wu F, Liu L, Zhou
Y, Zeng L, Zhou C, Xia C, Jiang W, et al: Efficacy and safety of
apatinib plus vinorelbine in patients with wild-type advanced
non-small cell lung cancer after second-line treatment failure: A
nonrandomized clinical trial. JAMA Netw Open.
3(e201226)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Howard FM and Pearson AT: Prognosis and
treatment of non-small cell lung cancer in the age of deep
learning. JAMA Netw Open. 3(e206368)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kukulj S, Aukst Margetic B, Jakovljevic M
and Samarzija M: Temperament and character and quality of life in
lung cancer patients. Tumori. 99:708–714. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Okamoto J, Kubokura H and Usuda J: Factors
determining the choice of surgical procedure in elderly patients
with non-small cell lung cancer. Ann Thorac Cardiovasc Surg.
22:131–138. 2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Chen K, Yang D, Li F, Gao L, Tian Y, Xu B,
Xu X, Xu Q and Cao J: Changes in the symptom clusters of elderly
patients with lung cancer over the course of postoperative
rehabilitation and their correlation with frailty and quality of
life: A longitudinal study. Eur J Oncol Nurs.
67(102388)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: Challenges and interventions. Chest.
143:1117–1126. 2023.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kwan SW, Mortell KE, Talenfeld AD and
Brunner MC: Thermal ablation matches sublobar resection outcomes in
older patients with early-stage non-small cell lung cancer. J Vasc
Interv Radiol. 25:1–9.e1. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Fang Z, He J, Fang W, Ruan L and Fang F:
Long-term outcomes of thoracoscopic anatomic resections and
systematic lymphadenectomy for elderly high-risk patients with
stage IB non-small-cell lung cancer. Heart Lung Circ. 25:392–397.
2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Ye X, Liu Y, Yang J, Wang Y, Cui X, Xie H,
Song L, Ding Z, Zhai R, Han Y, et al: Do older patients with stage
IB non-small-cell lung cancer obtain survival benefits from
surgery? A propensity score matching study using SEER data. Eur J
Surg Oncol. 48:1954–1963. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lee SM, Schulz C, Prabhash K, Kowalski D,
Szczesna A, Han B, Rittmeyer A, Talbot T, Vicente D, Califano R, et
al: First-line atezolizumab monotherapy versus single-agent
chemotherapy in patients with non-small-cell lung cancer ineligible
for treatment with a platinum-containing regimen (IPSOS): A phase
3, global, multicentre, open-label, randomised controlled study.
Lancet. 402:451–463. 2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Sun L, Zhao Q, Wang Y, Wang Y, Zheng M,
Ding X and Miao L: Efficacy and safety of anlotinib-containing
regimens in advanced non-small cell lung cancer: A real-world
study. Int J Gen Med. 16:4165–4179. 2023.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Kokkotou E, Anagnostakis M, Evangelou G,
Syrigos NK and Gkiozos I: Real-world data and evidence in lung
cancer: A review of recent developments. Cancers (Basel).
16(1414)2024.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Nobili S, Lavacchi D, Perrone G, Vicini G,
Tassi R, Landini I, Grosso A, Roviello G, Mazzanti R, Santomaggio C
and Mini E: Vinorelbine in non-small cell lung cancer: Real-World
data from a single-institution experience. Oncol Res. 28:237–248.
2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Wang M, Mao M, Yang Y, Cai Z, Li Y, Chen
Y, Cai J and Ye Q: Safety and efficacy of anlotinib hydrochloride
capsules in advanced non-small-cell lung cancer: A multicenter,
real-world study. Future Oncol. 19:1729–1739. 2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wei W, Ban X, Yang F, Li J, Cheng X, Zhang
R, Huang X, Huang Y, Li Q, Qiu Y, et al: Phase II trial of
efficacy, safety and biomarker analysis of sintilimab plus
anlotinib for patients with recurrent or advanced endometrial
cancer. J Immunother Cancer. 10(e004338)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jiang M, Zhang C, Hu Y, Li T, Yang G, Wang
G, Zhu J, Shao C, Hou H, Zhou N, et al: Anlotinib combined with
toripalimab as second-line therapy for advanced, relapsed gastric
or gastroesophageal junction carcinoma. Oncologist. 27:e856–e869.
2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Alshangiti A, Chandhoke G and Ellis PM:
Antiangiogenic therapies in non-small-cell lung cancer. Curr Oncol.
25 (Suppl 1):S45–S58. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Si X, Zhang L, Wang H, Zhang X, Wang M,
Han B, Li K, Wang Q, Shi J, Wang Z, et al: Management of
anlotinib-related adverse events in patients with advanced
non-small cell lung cancer: Experiences in ALTER-0303. Thorac
Cancer. 10:551–556. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Carlson K and Ocean AJ: Peripheral
neuropathy with microtubule-targeting agents: Occurrence and
management approach. Clin Breast Cancer. 11:73–81. 2011.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Noguchi E and Maeda Y:
Chemotherapy-induced peripheral neuropathy. Gan To Kagaku Ryoho.
38:1773–1776. 2011.PubMed/NCBI(In Japanese).
|
|
48
|
Xu B, Sun T, Wang S and Lin Y: Metronomic
therapy in advanced breast cancer and NSCLC: Vinorelbine as a
paradigm of recent progress. Expert Rev Anticancer Ther. 21:71–79.
2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Li X, Peng Y, Wu D, Tang J and Wu Y:
Efficacy and safety of anlotinib as maintenance therapy in patients
with advanced non-small cell lung cancer achieving SD post
first-line chemotherapy combined with immunotherapy. J Chemother:
Sep 1, 2024 (Epub ahead of print).
|
|
50
|
Glorieux C, Xia X, You X, Wang Z, Han Y,
Yang J, Noppe G, Meester C, Ling J, Robert A, et al: Cisplatin and
gemcitabine exert opposite effects on immunotherapy with PD-1
antibody in K-ras-driven cancer. J Adv Res. 40:109–124.
2022.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Blumberg N: Tumor angiogenesis factor.
Speculations on an approach to cancer chemotherapy. Yale J Biol
Med. 47:71–81. 1974.PubMed/NCBI
|
|
52
|
Cabebe E and Wakelee H: Role of
anti-angiogenesis agents in treating NSCLC: Focus on bevacizumab
and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol.
8:15–27. 2007.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Zhang Y, Yang SH and Guo XL: New insights
into Vinca alkaloids resistance mechanism and circumvention in lung
cancer. Biomed Pharmacother. 96:659–666. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Laquente B, Viñals F and Germà JR:
Metronomic chemotherapy: An antiangiogenic scheduling. Clin Transl
Oncol. 9:93–98. 2007.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Wang J, Li X, Zhou J, Qiu D, Zhang M, Sun
L and Li SC: Long-term survival with anlotinib as a front-line
treatment in an elderly NSCLC patient: A case report. Front Oncol.
13(1043244)2023.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Qiang H, Chang Q, Xu J, Qian J, Zhang Y,
Lei Y, Han B and Chu T: New advances in antiangiogenic combination
therapeutic strategies for advanced non-small cell lung cancer. J
Cancer Res Clin Oncol. 146:631–645. 2020.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Li X, Wu D, Tang J and Wu Y: The
efficiency and safety of temozolomide and PD-1/L1 inhibitors in
pretreated NSCLC with brain metastasis: A retrospective cohort. J
Cancer Res Clin Oncol. 150(271)2024.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Niu Z, Jin R, Zhang Y and Li H: Signaling
pathways and targeted therapies in lung squamous cell carcinoma:
Mechanisms and clinical trials. Signal Transduct Target Ther.
7(353)2022.PubMed/NCBI View Article : Google Scholar
|
